Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates

March 15, 2022

Enveric Biosciences to Participate in Upcoming Investor Conferences in March 2022

March 3, 2022

Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules

March 1, 2022

Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress

February 17, 2022

Enveric Biosciences Announces Closing of $10 Million Public Offering

February 15, 2022

Enveric Biosciences Announces Pricing of $10 Million Public Offering

February 11, 2022

Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 – Cannabinoid + Celecoxib Conjugate

February 8, 2022

Enveric Biosciences to Participate in Upcoming Investor Conferences in February 2022

January 27, 2022

Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders

January 18, 2022

Enveric Biosciences to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022

January 6, 2022

‹
1
…
13
14
15
16
17
18
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2026 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.